Abstract
Previous study reported that patients treated with axitinib as second-line therapy had longer median progression-free survival than those treated with sorafenib for metastatic renal cell carcinoma (mRCC). In this study, we reviewed our experience of axitinib as a first-line therapy for mRCC in Japanese patients, focusing on its efficacy and safety. We retrospectively assessed 26 patients treated with axitinib as a first-line therapy for mRCC from July 2010 to July 2014 at Chiba Cancer Center and Kinki University Hospital. Observation period was 24.6 ± 18.3 months. The objective response rate was 50.0%, and the median progression-free survival was 27.5 months. Overall survival was not estimable. Common grade 3 adverse events were hypertension in 19 patients and proteinuria in 5 patients. Axitinib demonstrated significant efficacy as a first-line therapy in Japanese patients with mRCC. Careful monitoring and management of the adverse effects may help to control its toxicities.
Highlights
Renal cell carcinoma (RCC) is highly resistant to chemotherapy
We retrospectively assessed 26 patients who had been treated with axitinib as a first-line therapy for the treatment of metastatic RCC (mRCC) between July 2010 and July 2014 at Chiba Cancer Center (CCC) and Kinki University Hospital (KUH). 14 of the patients had enrolled in a phase II trial that assessed the efficacy and safety of axitinib dose titration (NCT00835978) [7]
We did not examine the responses of three patients who had bone metastases only in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Summary
Renal cell carcinoma (RCC) is highly resistant to chemotherapy. Cytokine therapies, including interferon-α andHow to cite this paper: Namekawa, T., Fukasawa, S., Komaru, A., Kobayashi, M., Ohzeki, T., Sato, Y., Rii, J., Uemura, H., Ichikawa, T. and Ueda, T. (2015) Efficacy and Safety of Axitinib as First-Line Therapy in Japanese Patients with Metastatic Renal Cell Carcinoma. (2015) Efficacy and Safety of Axitinib as First-Line Therapy in Japanese Patients with Metastatic Renal Cell Carcinoma. The development of antiangiogenic drugs that target vascular endothelial growth factor (VEGF) receptors was based on extensive investigations into the molecular mechanisms underlying RCC. These drugs with proven benefits in the treatment of mRCC have been approved, and they include sunitinib, sorafenib, pazopanib, and axitinib [2]-[4]. Selective second-generation inhibitor of VEGF receptors that has shown efficacy in phase II and III clinical trials in patients with mRCC who had been treated previously [4]-[7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
